Guardant Health (GH) CMO Craig Eagle reports RSU vesting and tax share sale

Rhea-AI Filing Summary

Guardant Health, Inc. reported an insider equity transaction by its Chief Medical Officer, Craig Eagle. On 12/15/2025, 1,402 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of previously granted restricted stock units. On the same date, 711 shares were disposed of at $102.67 per share, retained by the company to cover tax withholding obligations related to this vesting.

Following these transactions, Craig Eagle beneficially owned 45,007 shares of Guardant Health common stock directly, and held 2,804 restricted stock units as derivative securities. The underlying restricted stock unit award was granted on June 9, 2023 and vests over a three-year period, with 33% having vested on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EAGLE CRAIG

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		M		1,402	A	$0	45,718	D
Common Stock	12/15/2025		F		711(1)	D	$102.67	45,007	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	12/15/2025		M			1,402	(2)	(3)	Common Stock	1,402	$0	2,804	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

3. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Craig Eagle	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Guardant Health (GH) report for Craig Eagle?

Guardant Health reported that Chief Medical Officer Craig Eagle acquired 1,402 shares of common stock on 12/15/2025 through the vesting and settlement of restricted stock units, and disposed of 711 shares the same day to satisfy tax withholding obligations.

How many Guardant Health (GH) shares does Craig Eagle own after this Form 4 filing?

After the reported transactions, Craig Eagle beneficially owned 45,007 shares of Guardant Health common stock directly and held 2,804 restricted stock units as derivative securities.

What was the purpose of the 711 Guardant Health (GH) shares disposed of?

The 711 shares were retained by Guardant Health to meet Craig Eagle’s tax withholding obligations in connection with the vesting of a restricted stock unit installment. The amount retained was not in excess of the tax liability.

At what price were Craig Eagle’s Guardant Health (GH) shares withheld for taxes?

The 711 shares withheld to satisfy tax obligations were valued at a price of $102.67 per share in the reported transaction.

How do Craig Eagle’s restricted stock units in Guardant Health (GH) vest?

The reported restricted stock unit award was granted on June 9, 2023. 33% of the shares vested on June 15, 2024, and the remaining 67% vest in equal quarterly installments over the following two years.

What position does the reporting person hold at Guardant Health (GH)?

The reporting person, Craig Eagle, is an officer of Guardant Health and serves as the company’s Chief Medical Officer.